| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Kinnate Biopharma Inc. | CHIEF EXECUTIVE OFFICER, Director | Common Stock | 0 | $0 | $2.59 | Apr 3, 2024 | Direct |
| Keros Therapeutics, Inc. | Director | Stock Option (right to buy) | 10K | May 30, 2024 | Direct | ||
| Kinnate Biopharma Inc. | CHIEF EXECUTIVE OFFICER, Director | Stock Option (right to buy) | 0 | Apr 3, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | May 30, 2024 | 1 | $0 | 4 | Jun 3, 2024 | Director |
| KNTE | Kinnate Biopharma Inc. | Apr 3, 2024 | 6 | $0 | 4 | Apr 5, 2024 | CHIEF EXECUTIVE OFFICER, Director |
| KROS | Keros Therapeutics, Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director |
| KNTE | Kinnate Biopharma Inc. | Feb 10, 2023 | 1 | $0 | 4/A | Feb 15, 2023 | Chief Executive Officer, Director |
| KROS | Keros Therapeutics, Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 3, 2022 | Director |
| KNTE | Kinnate Biopharma Inc. | Feb 11, 2022 | 1 | $0 | 4 | Feb 15, 2022 | Chief Executive Officer, Director |
| KROS | Keros Therapeutics, Inc. | Jun 1, 2021 | 1 | $0 | 4 | Jun 3, 2021 | Director |